LIPO
LIPELLA PHARMACEUTICALS INC.Company Information
- Company Name
- LIPELLA PHARMACEUTICALS INC.
- CIK
- CIK0001347242
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- LIPO: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LIPO
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-05-14
- Last sale
- —
- Shares purchased (TTM)
- 35,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2025-03-31
- Institutional shares owned
- 2,840
- Shares outstanding
- 2,056,804
- Ownership
- 0.14%
Earnings Market Reaction
- Filing date
- 2025-11-14
- Price on filing date
- —
- 1-month reaction
- -42.78%
- 3-month reaction
- -46.67%
Balance Sheet
Values in millions ($)| Line item | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 2 | 3 | 4 | 2 | 1 | 1 | 2 | 3 | 2 | 3 | 4 | 5 | ||||||
| Accounts Receivable Net Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Grants Receivable Current | - | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | ||||||
| Assets Current | 2 | 3 | 5 | 3 | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 6 | ||||||
| Furniture And Fixtures Gross | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | 0 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | - | - | -0 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 2 | 4 | 5 | 3 | 2 | 2 | 3 | 4 | 3 | 3 | 5 | 6 | ||||||
| Other Assets | - | - | - | - | - | - | - | 0 | 0 | - | - | 0 | ||||||
| Accounts Payable Current | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Accrued Liabilities Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Other Liabilities Current | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Liabilities | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | - | - | - | 0 | - | - | - | - | - | - | - | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 21 | 21 | 21 | 17 | 15 | 14 | 14 | 13 | 12 | 11 | 11 | 10 | ||||||
| Retained Earnings Accumulated Deficit | -19 | -18 | -17 | -15 | -14 | -12 | -12 | -10 | -10 | -8 | -7 | -6 | ||||||
| Stockholders Equity | 1 | 3 | 4 | 2 | 1 | 2 | 3 | 3 | 2 | 3 | 4 | 5 | ||||||
| Liabilities And Stockholders Equity | 2 | 4 | 5 | 3 | 2 | 2 | 3 | 4 | 3 | 3 | 5 | 6 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | ||||||
| Preferred Stock Shares Issued | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 5 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Shares Outstanding | 5 | 4 | 3 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLIPELLA PHARMACEUTICALS INC. (LIPO) — SEC Financial Statements & Analysis
LIPELLA PHARMACEUTICALS INC. (LIPO) is a pharmaceutical preparations company, incorporated in DE. LIPELLA PHARMACEUTICALS INC. trades on OTC as: LIPO. LIPELLA PHARMACEUTICALS INC. (LIPO)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14. Based on that filing, LIPELLA PHARMACEUTICALS INC. carries a market cap of $2.73M, a P/E ratio of -0.51x, a P/B ratio of 1.83x, a P/S ratio of 4.50x, an enterprise value of $873.70K, and an EV/EBITDA multiple of -0.16x. On profitability, it posts a gross margin of 102.41%, an operating margin of -892.88%, a net margin of -879.64%, a Return on Equity (ROE) of -361.77%, a Return on Assets (ROA) of -236.36%, and a Return on Invested Capital (ROIC) of -1578.89%. Per share, it reports EPS of $-1.17, diluted EPS of $-1.17, free cash flow per share of $-1.05, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 25.31% year-over-year, net income growth of 25.01% year-over-year, and EPS growth of -69.25% year-over-year. On the balance sheet, it maintains a current ratio of 3.24x, a quick ratio of 2.89x, working capital of $1.44M, a debt-to-equity ratio of 0.58x, a debt ratio of 0.37, an interest coverage ratio of -401.81x, free cash flow of $-4.78M (TTM), and net debt of $-1.86M. Figures sourced from SEC EDGAR.
- Market Cap
- $2.73M
- P/E TTM
- -0.51x
- EPS TTM
- $-1.17
- P/B TTM
- 1.83x
- ROE TTM
- -361.77%
- ROA TTM
- -236.36%
- Debt To Equity
- 0.58x
- Free Cash Flow TTM
- $-4.78M
- Net Revenue TTM Growth 1Y
- 25.31%
Data as of 2025-09-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is LIPELLA PHARMACEUTICALS INC. in?
LIPELLA PHARMACEUTICALS INC. (LIPO) operates in the Pharmaceutical Preparations industry.
What exchange does LIPO trade on?
LIPELLA PHARMACEUTICALS INC. (LIPO) trades on the OTC.
Where is LIPELLA PHARMACEUTICALS INC. incorporated?
LIPELLA PHARMACEUTICALS INC. is incorporated in DE.
When was LIPELLA PHARMACEUTICALS INC. (LIPO)'s most recent SEC filing?
LIPELLA PHARMACEUTICALS INC. (LIPO)'s most recent SEC filing is a Form 10-Q for the period ended 2025-09-30, filed with the SEC on 2025-11-14.
What is LIPO's market cap?
LIPELLA PHARMACEUTICALS INC. (LIPO) has a market capitalization of $2.73M as of 2025-09-30.
What is LIPO's EPS (earnings per share)?
LIPELLA PHARMACEUTICALS INC. (LIPO)'s trailing twelve month EPS is $-1.17 as of 2025-09-30.
What is LIPO's ROE (return on equity)?
LIPELLA PHARMACEUTICALS INC. (LIPO)'s trailing twelve month Return on Equity (ROE) is -361.77% as of 2025-09-30.
What is LIPO's ROA (return on assets)?
LIPELLA PHARMACEUTICALS INC. (LIPO)'s trailing twelve month Return on Assets (ROA) is -236.36% as of 2025-09-30.
What is LIPO's ROIC (return on invested capital)?
LIPELLA PHARMACEUTICALS INC. (LIPO)'s trailing twelve month Return on Invested Capital (ROIC) is -1578.89% as of 2024-06-30.
What is LIPO's EV/EBITDA?
LIPELLA PHARMACEUTICALS INC. (LIPO)'s trailing twelve month EV/EBITDA is -0.16x as of 2025-09-30.